#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Dorsal anterior cingulate glutamate is associated with engagement of the default mode network during exposure to smoking cues Background When exposed to smoking cues, nicotine dependent individuals activate brain regions overlapping with the default mode network (DMN), a network of regions involved in internally-focused cognition.
1-1	0-6	Dorsal	_
1-2	7-15	anterior	_
1-3	16-25	cingulate	_
1-4	26-35	glutamate	_
1-5	36-38	is	_
1-6	39-49	associated	_
1-7	50-54	with	_
1-8	55-65	engagement	_
1-9	66-68	of	_
1-10	69-72	the	_
1-11	73-80	default	_
1-12	81-85	mode	_
1-13	86-93	network	_
1-14	94-100	during	_
1-15	101-109	exposure	_
1-16	110-112	to	_
1-17	113-120	smoking	_
1-18	121-125	cues	_
1-19	126-136	Background	_
1-20	137-141	When	_
1-21	142-149	exposed	_
1-22	150-152	to	_
1-23	153-160	smoking	_
1-24	161-165	cues	_
1-25	166-167	,	_
1-26	168-176	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
1-27	177-186	dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
1-28	187-198	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
1-29	199-207	activate	_
1-30	208-213	brain	_
1-31	214-221	regions	_
1-32	222-233	overlapping	_
1-33	234-238	with	_
1-34	239-242	the	_
1-35	243-250	default	_
1-36	251-255	mode	_
1-37	256-263	network	_
1-38	264-265	(	_
1-39	266-269	DMN	_
1-40	270-271	)	_
1-41	272-273	,	_
1-42	274-275	a	_
1-43	276-283	network	_
1-44	284-286	of	_
1-45	287-294	regions	_
1-46	295-303	involved	_
1-47	304-306	in	_
1-48	307-325	internally-focused	_
1-49	326-335	cognition	_
1-50	336-337	.	_

Text=The salience network (SN), which includes the dorsal anterior cingulate cortex (dACC), is thought to interact with the DMN and aids in directing attention toward salient internal or external stimuli.
2-1	338-341	The	_
2-2	342-350	salience	_
2-3	351-358	network	_
2-4	359-360	(	_
2-5	361-363	SN	_
2-6	364-365	)	_
2-7	366-367	,	_
2-8	368-373	which	_
2-9	374-382	includes	_
2-10	383-386	the	_
2-11	387-393	dorsal	_
2-12	394-402	anterior	_
2-13	403-412	cingulate	_
2-14	413-419	cortex	_
2-15	420-421	(	_
2-16	422-426	dACC	_
2-17	427-428	)	_
2-18	429-430	,	_
2-19	431-433	is	_
2-20	434-441	thought	_
2-21	442-444	to	_
2-22	445-453	interact	_
2-23	454-458	with	_
2-24	459-462	the	_
2-25	463-466	DMN	_
2-26	467-470	and	_
2-27	471-475	aids	_
2-28	476-478	in	_
2-29	479-488	directing	_
2-30	489-498	attention	_
2-31	499-505	toward	_
2-32	506-513	salient	_
2-33	514-522	internal	_
2-34	523-525	or	_
2-35	526-534	external	_
2-36	535-542	stimuli	_
2-37	543-544	.	_

Text=One possibility is that neurochemical variation in SN regions such as the dACC impact DMN reactivity to personally relevant stimuli such as smoking cues.
3-1	545-548	One	_
3-2	549-560	possibility	_
3-3	561-563	is	_
3-4	564-568	that	_
3-5	569-582	neurochemical	_
3-6	583-592	variation	_
3-7	593-595	in	_
3-8	596-598	SN	_
3-9	599-606	regions	_
3-10	607-611	such	_
3-11	612-614	as	_
3-12	615-618	the	_
3-13	619-623	dACC	_
3-14	624-630	impact	_
3-15	631-634	DMN	_
3-16	635-645	reactivity	_
3-17	646-648	to	_
3-18	649-659	personally	_
3-19	660-668	relevant	_
3-20	669-676	stimuli	_
3-21	677-681	such	_
3-22	682-684	as	_
3-23	685-692	smoking	_
3-24	693-697	cues	_
3-25	698-699	.	_

Text=This is consistent with emerging evidence suggesting an association between midline cortical glutamate (Glu) and activity in brain regions overlapping with the DMN.
4-1	700-704	This	_
4-2	705-707	is	_
4-3	708-718	consistent	_
4-4	719-723	with	_
4-5	724-732	emerging	_
4-6	733-741	evidence	_
4-7	742-752	suggesting	_
4-8	753-755	an	_
4-9	756-767	association	_
4-10	768-775	between	_
4-11	776-783	midline	_
4-12	784-792	cortical	_
4-13	793-802	glutamate	_
4-14	803-804	(	_
4-15	805-808	Glu	_
4-16	809-810	)	_
4-17	811-814	and	_
4-18	815-823	activity	_
4-19	824-826	in	_
4-20	827-832	brain	_
4-21	833-840	regions	_
4-22	841-852	overlapping	_
4-23	853-857	with	_
4-24	858-861	the	_
4-25	862-865	DMN	_
4-26	866-867	.	_

Text=Methods In 18 nicotine-dependent individuals, we assessed the relationship between DMN activation to smoking relative to neutral cues using functional magnetic resonance imaging and dACC Glu as measured by magnetic resonance spectroscopy.
5-1	868-875	Methods	_
5-2	876-878	In	_
5-3	879-881	18	_
5-4	882-900	nicotine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
5-5	901-912	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
5-6	913-914	,	_
5-7	915-917	we	_
5-8	918-926	assessed	_
5-9	927-930	the	_
5-10	931-943	relationship	_
5-11	944-951	between	_
5-12	952-955	DMN	_
5-13	956-966	activation	_
5-14	967-969	to	_
5-15	970-977	smoking	_
5-16	978-986	relative	_
5-17	987-989	to	_
5-18	990-997	neutral	_
5-19	998-1002	cues	_
5-20	1003-1008	using	_
5-21	1009-1019	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-22	1020-1028	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-23	1029-1038	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-24	1039-1046	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-25	1047-1050	and	_
5-26	1051-1055	dACC	_
5-27	1056-1059	Glu	_
5-28	1060-1062	as	_
5-29	1063-1071	measured	_
5-30	1072-1074	by	_
5-31	1075-1083	magnetic	_
5-32	1084-1093	resonance	_
5-33	1094-1106	spectroscopy	_
5-34	1107-1108	.	_

Text=This association also was tested in a replication sample of 14 nicotine-dependent participants.
6-1	1109-1113	This	_
6-2	1114-1125	association	_
6-3	1126-1130	also	_
6-4	1131-1134	was	_
6-5	1135-1141	tested	_
6-6	1142-1144	in	_
6-7	1145-1146	a	_
6-8	1147-1158	replication	_
6-9	1159-1165	sample	_
6-10	1166-1168	of	_
6-11	1169-1171	14	_
6-12	1172-1190	nicotine-dependent	_
6-13	1191-1203	participants	_
6-14	1204-1205	.	_

Text=Results Not only was the DMN significantly less suppressed during smoking cue exposure, but also there was a positive association between DMN reactivity to smoking relative to neutral cues and dACC Glu (r = 0.56, p <0.02).
7-1	1206-1213	Results	_
7-2	1214-1217	Not	_
7-3	1218-1222	only	_
7-4	1223-1226	was	_
7-5	1227-1230	the	_
7-6	1231-1234	DMN	_
7-7	1235-1248	significantly	_
7-8	1249-1253	less	_
7-9	1254-1264	suppressed	_
7-10	1265-1271	during	_
7-11	1272-1279	smoking	_
7-12	1280-1283	cue	_
7-13	1284-1292	exposure	_
7-14	1293-1294	,	_
7-15	1295-1298	but	_
7-16	1299-1303	also	_
7-17	1304-1309	there	_
7-18	1310-1313	was	_
7-19	1314-1315	a	_
7-20	1316-1324	positive	_
7-21	1325-1336	association	_
7-22	1337-1344	between	_
7-23	1345-1348	DMN	_
7-24	1349-1359	reactivity	_
7-25	1360-1362	to	_
7-26	1363-1370	smoking	_
7-27	1371-1379	relative	_
7-28	1380-1382	to	_
7-29	1383-1390	neutral	_
7-30	1391-1395	cues	_
7-31	1396-1399	and	_
7-32	1400-1404	dACC	_
7-33	1405-1408	Glu	_
7-34	1409-1410	(	_
7-35	1411-1412	r	_
7-36	1413-1414	=	_
7-37	1415-1419	0.56	_
7-38	1420-1421	,	_
7-39	1422-1423	p	_
7-40	1424-1425	<	_
7-41	1426-1430	0.02	_
7-42	1431-1432	)	_
7-43	1433-1434	.	_

Text=This finding was confirmed in the independent replication cohort (r = 0.64, p <0.02).
8-1	1435-1439	This	_
8-2	1440-1447	finding	_
8-3	1448-1451	was	_
8-4	1452-1461	confirmed	_
8-5	1462-1464	in	_
8-6	1465-1468	the	_
8-7	1469-1480	independent	_
8-8	1481-1492	replication	_
8-9	1493-1499	cohort	_
8-10	1500-1501	(	_
8-11	1502-1503	r	_
8-12	1504-1505	=	_
8-13	1506-1510	0.64	_
8-14	1511-1512	,	_
8-15	1513-1514	p	_
8-16	1515-1516	<	_
8-17	1517-1521	0.02	_
8-18	1522-1523	)	_
8-19	1524-1525	.	_

Text=Conclusions The current findings confirm that the DMN is less suppressed when smokers view smoking relative to neutral cues, suggesting that smoking cues engage self-relevant processing.
9-1	1526-1537	Conclusions	_
9-2	1538-1541	The	_
9-3	1542-1549	current	_
9-4	1550-1558	findings	_
9-5	1559-1566	confirm	_
9-6	1567-1571	that	_
9-7	1572-1575	the	_
9-8	1576-1579	DMN	_
9-9	1580-1582	is	_
9-10	1583-1587	less	_
9-11	1588-1598	suppressed	_
9-12	1599-1603	when	_
9-13	1604-1611	smokers	_
9-14	1612-1616	view	_
9-15	1617-1624	smoking	_
9-16	1625-1633	relative	_
9-17	1634-1636	to	_
9-18	1637-1644	neutral	_
9-19	1645-1649	cues	_
9-20	1650-1651	,	_
9-21	1652-1662	suggesting	_
9-22	1663-1667	that	_
9-23	1668-1675	smoking	_
9-24	1676-1680	cues	_
9-25	1681-1687	engage	_
9-26	1688-1701	self-relevant	_
9-27	1702-1712	processing	_
9-28	1713-1714	.	_

Text=Furthermore, these results indicate that dACC Glu is associated with enhanced DMN engagement when nicotine-dependent individuals are exposed to self-relevant smoking cues.
10-1	1715-1726	Furthermore	_
10-2	1727-1728	,	_
10-3	1729-1734	these	_
10-4	1735-1742	results	_
10-5	1743-1751	indicate	_
10-6	1752-1756	that	_
10-7	1757-1761	dACC	_
10-8	1762-1765	Glu	_
10-9	1766-1768	is	_
10-10	1769-1779	associated	_
10-11	1780-1784	with	_
10-12	1785-1793	enhanced	_
10-13	1794-1797	DMN	_
10-14	1798-1808	engagement	_
10-15	1809-1813	when	_
10-16	1814-1832	nicotine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
10-17	1833-1844	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
10-18	1845-1848	are	_
10-19	1849-1856	exposed	_
10-20	1857-1859	to	_
10-21	1860-1873	self-relevant	_
10-22	1874-1881	smoking	_
10-23	1882-1886	cues	_
10-24	1887-1888	.	_

Text=2.
11-1	1889-1890	2	_
11-2	1891-1892	.	_

Text=MATERIALS AND METHODS 2.1 Participants Data were evaluated in two independent samples of individuals who participated in all study elements at McLean Hospital ’ s Imaging Center.
12-1	1893-1902	MATERIALS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-2	1903-1906	AND	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-3	1907-1914	METHODS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-4	1915-1918	2.1	_
12-5	1919-1931	Participants	_
12-6	1932-1936	Data	_
12-7	1937-1941	were	_
12-8	1942-1951	evaluated	_
12-9	1952-1954	in	_
12-10	1955-1958	two	_
12-11	1959-1970	independent	_
12-12	1971-1978	samples	_
12-13	1979-1981	of	_
12-14	1982-1993	individuals	_
12-15	1994-1997	who	_
12-16	1998-2010	participated	_
12-17	2011-2013	in	_
12-18	2014-2017	all	_
12-19	2018-2023	study	_
12-20	2024-2032	elements	_
12-21	2033-2035	at	_
12-22	2036-2042	McLean	_
12-23	2043-2051	Hospital	_
12-24	2052-2053	’	_
12-25	2054-2055	s	_
12-26	2056-2063	Imaging	_
12-27	2064-2070	Center	_
12-28	2071-2072	.	_

Text=The primary analysis was conducted using data from our prior work where nicotine dependent individuals were exposed to smoking vs. neutral cues, while our replication cohort was exposed to smoking vs. neutral cues within the context of a working memory task.
13-1	2073-2076	The	_
13-2	2077-2084	primary	_
13-3	2085-2093	analysis	_
13-4	2094-2097	was	_
13-5	2098-2107	conducted	_
13-6	2108-2113	using	_
13-7	2114-2118	data	_
13-8	2119-2123	from	_
13-9	2124-2127	our	_
13-10	2128-2133	prior	_
13-11	2134-2138	work	_
13-12	2139-2144	where	_
13-13	2145-2153	nicotine	_
13-14	2154-2163	dependent	_
13-15	2164-2175	individuals	_
13-16	2176-2180	were	_
13-17	2181-2188	exposed	_
13-18	2189-2191	to	_
13-19	2192-2199	smoking	_
13-20	2200-2203	vs.	_
13-21	2204-2211	neutral	_
13-22	2212-2216	cues	_
13-23	2217-2218	,	_
13-24	2219-2224	while	_
13-25	2225-2228	our	_
13-26	2229-2240	replication	_
13-27	2241-2247	cohort	_
13-28	2248-2251	was	_
13-29	2252-2259	exposed	_
13-30	2260-2262	to	_
13-31	2263-2270	smoking	_
13-32	2271-2274	vs.	_
13-33	2275-2282	neutral	_
13-34	2283-2287	cues	_
13-35	2288-2294	within	_
13-36	2295-2298	the	_
13-37	2299-2306	context	_
13-38	2307-2309	of	_
13-39	2310-2311	a	_
13-40	2312-2319	working	_
13-41	2320-2326	memory	_
13-42	2327-2331	task	_
13-43	2332-2333	.	_

Text=Our primary cohort was comprised of 18 nicotine-dependent individuals aged 31.4 ± 1.4 years (10 women / 8 men), while our replication cohort was comprised of 14 nicotine-dependent individuals aged 26 ± 1.22 years (8 women / 6 men).
14-1	2334-2337	Our	_
14-2	2338-2345	primary	_
14-3	2346-2352	cohort	_
14-4	2353-2356	was	_
14-5	2357-2366	comprised	_
14-6	2367-2369	of	_
14-7	2370-2372	18	_
14-8	2373-2391	nicotine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
14-9	2392-2403	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
14-10	2404-2408	aged	_
14-11	2409-2413	31.4	_
14-12	2414-2415	±	_
14-13	2416-2419	1.4	_
14-14	2420-2425	years	_
14-15	2426-2427	(	_
14-16	2428-2430	10	_
14-17	2431-2436	women	_
14-18	2437-2438	/	_
14-19	2439-2440	8	_
14-20	2441-2444	men	_
14-21	2445-2446	)	_
14-22	2447-2448	,	_
14-23	2449-2454	while	_
14-24	2455-2458	our	_
14-25	2459-2470	replication	_
14-26	2471-2477	cohort	_
14-27	2478-2481	was	_
14-28	2482-2491	comprised	_
14-29	2492-2494	of	_
14-30	2495-2497	14	_
14-31	2498-2516	nicotine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
14-32	2517-2528	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
14-33	2529-2533	aged	_
14-34	2534-2536	26	_
14-35	2537-2538	±	_
14-36	2539-2543	1.22	_
14-37	2544-2549	years	_
14-38	2550-2551	(	_
14-39	2552-2553	8	_
14-40	2554-2559	women	_
14-41	2560-2561	/	_
14-42	2562-2563	6	_
14-43	2564-2567	men	_
14-44	2568-2569	)	_
14-45	2570-2571	.	_

Text=Both cohorts were moderately nicotine dependent as indicated by the Fagerstrom test of nicotine dependence and reported smoking ≥10 cig/day over the last 6 months.
15-1	2572-2576	Both	_
15-2	2577-2584	cohorts	_
15-3	2585-2589	were	_
15-4	2590-2600	moderately	_
15-5	2601-2609	nicotine	_
15-6	2610-2619	dependent	_
15-7	2620-2622	as	_
15-8	2623-2632	indicated	_
15-9	2633-2635	by	_
15-10	2636-2639	the	_
15-11	2640-2650	Fagerstrom	_
15-12	2651-2655	test	_
15-13	2656-2658	of	_
15-14	2659-2667	nicotine	_
15-15	2668-2678	dependence	_
15-16	2679-2682	and	_
15-17	2683-2691	reported	_
15-18	2692-2699	smoking	_
15-19	2700-2703	≥10	_
15-20	2704-2711	cig/day	_
15-21	2712-2716	over	_
15-22	2717-2720	the	_
15-23	2721-2725	last	_
15-24	2726-2727	6	_
15-25	2728-2734	months	_
15-26	2735-2736	.	_

Text=Smoking status was confirmed by expired carbon monoxide immediately upon entering the study (CO: Micro Smokerlyzer II, Bedfont Scientific Instruments, Kent UK).
16-1	2737-2744	Smoking	_
16-2	2745-2751	status	_
16-3	2752-2755	was	_
16-4	2756-2765	confirmed	_
16-5	2766-2768	by	_
16-6	2769-2776	expired	_
16-7	2777-2783	carbon	_
16-8	2784-2792	monoxide	_
16-9	2793-2804	immediately	_
16-10	2805-2809	upon	_
16-11	2810-2818	entering	_
16-12	2819-2822	the	_
16-13	2823-2828	study	_
16-14	2829-2830	(	_
16-15	2831-2833	CO	_
16-16	2834-2835	:	_
16-17	2836-2841	Micro	_
16-18	2842-2853	Smokerlyzer	_
16-19	2854-2856	II	_
16-20	2857-2858	,	_
16-21	2859-2866	Bedfont	_
16-22	2867-2877	Scientific	_
16-23	2878-2889	Instruments	_
16-24	2890-2891	,	_
16-25	2892-2896	Kent	_
16-26	2897-2899	UK	_
16-27	2900-2901	)	_
16-28	2902-2903	.	_

Text=For full demographics see table 1.
17-1	2904-2907	For	_
17-2	2908-2912	full	_
17-3	2913-2925	demographics	_
17-4	2926-2929	see	_
17-5	2930-2935	table	_
17-6	2936-2937	1	_
17-7	2938-2939	.	_

Text=The structured clinical interview for DSM IV-TR was used to exclude participants with the following conditions: organic mental disorder, bipolar disorder, and schizophrenia spectrum disorder.
18-1	2940-2943	The	_
18-2	2944-2954	structured	_
18-3	2955-2963	clinical	_
18-4	2964-2973	interview	_
18-5	2974-2977	for	_
18-6	2978-2981	DSM	_
18-7	2982-2987	IV-TR	_
18-8	2988-2991	was	_
18-9	2992-2996	used	_
18-10	2997-2999	to	_
18-11	3000-3007	exclude	_
18-12	3008-3020	participants	_
18-13	3021-3025	with	_
18-14	3026-3029	the	_
18-15	3030-3039	following	_
18-16	3040-3050	conditions	_
18-17	3051-3052	:	_
18-18	3053-3060	organic	_
18-19	3061-3067	mental	_
18-20	3068-3076	disorder	_
18-21	3077-3078	,	_
18-22	3079-3086	bipolar	_
18-23	3087-3095	disorder	_
18-24	3096-3097	,	_
18-25	3098-3101	and	_
18-26	3102-3115	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
18-27	3116-3124	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
18-28	3125-3133	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
18-29	3134-3135	.	_

Text=Participants also were excluded for a substance use disorder other than nicotine dependence, current depressive episode, psychotropic drug use, pregnancy, and were required to have a zero blood alcohol level as measured by a breath sample (Alco-Sensor IV, Intoximeters, St Louis, MO).
19-1	3136-3148	Participants	_
19-2	3149-3153	also	_
19-3	3154-3158	were	_
19-4	3159-3167	excluded	_
19-5	3168-3171	for	_
19-6	3172-3173	a	_
19-7	3174-3183	substance	_
19-8	3184-3187	use	_
19-9	3188-3196	disorder	_
19-10	3197-3202	other	_
19-11	3203-3207	than	_
19-12	3208-3216	nicotine	_
19-13	3217-3227	dependence	_
19-14	3228-3229	,	_
19-15	3230-3237	current	_
19-16	3238-3248	depressive	_
19-17	3249-3256	episode	_
19-18	3257-3258	,	_
19-19	3259-3271	psychotropic	_
19-20	3272-3276	drug	_
19-21	3277-3280	use	_
19-22	3281-3282	,	_
19-23	3283-3292	pregnancy	_
19-24	3293-3294	,	_
19-25	3295-3298	and	_
19-26	3299-3303	were	_
19-27	3304-3312	required	_
19-28	3313-3315	to	_
19-29	3316-3320	have	_
19-30	3321-3322	a	_
19-31	3323-3327	zero	_
19-32	3328-3333	blood	_
19-33	3334-3341	alcohol	_
19-34	3342-3347	level	_
19-35	3348-3350	as	_
19-36	3351-3359	measured	_
19-37	3360-3362	by	_
19-38	3363-3364	a	_
19-39	3365-3371	breath	_
19-40	3372-3378	sample	_
19-41	3379-3380	(	_
19-42	3381-3392	Alco-Sensor	_
19-43	3393-3395	IV	_
19-44	3396-3397	,	_
19-45	3398-3410	Intoximeters	_
19-46	3411-3412	,	_
19-47	3413-3415	St	_
19-48	3416-3421	Louis	_
19-49	3422-3423	,	_
19-50	3424-3426	MO	_
19-51	3427-3428	)	_
19-52	3429-3430	.	_

Text=All participants gave verbal and written consent prior to participating in any study procedures and this research was approved by the Partners Human Research Committee, which is the institutional review board of Partners Healthcare hospitals.
20-1	3431-3434	All	_
20-2	3435-3447	participants	_
20-3	3448-3452	gave	_
20-4	3453-3459	verbal	_
20-5	3460-3463	and	_
20-6	3464-3471	written	_
20-7	3472-3479	consent	_
20-8	3480-3485	prior	_
20-9	3486-3488	to	_
20-10	3489-3502	participating	_
20-11	3503-3505	in	_
20-12	3506-3509	any	_
20-13	3510-3515	study	_
20-14	3516-3526	procedures	_
20-15	3527-3530	and	_
20-16	3531-3535	this	_
20-17	3536-3544	research	_
20-18	3545-3548	was	_
20-19	3549-3557	approved	_
20-20	3558-3560	by	_
20-21	3561-3564	the	_
20-22	3565-3573	Partners	_
20-23	3574-3579	Human	_
20-24	3580-3588	Research	_
20-25	3589-3598	Committee	_
20-26	3599-3600	,	_
20-27	3601-3606	which	_
20-28	3607-3609	is	_
20-29	3610-3613	the	_
20-30	3614-3627	institutional	_
20-31	3628-3634	review	_
20-32	3635-3640	board	_
20-33	3641-3643	of	_
20-34	3644-3652	Partners	_
20-35	3653-3663	Healthcare	_
20-36	3664-3673	hospitals	_
20-37	3674-3675	.	_

Text=2.2 Functional Neuroimaging To standardize the time since a cigarette was last smoked relative to all study procedures, all participants in both cohorts smoked one of their own cigarettes after signing the informed consent approximately 1.5 hours prior to MR scanning.
21-1	3676-3679	2.2	_
21-2	3680-3690	Functional	_
21-3	3691-3703	Neuroimaging	_
21-4	3704-3706	To	_
21-5	3707-3718	standardize	_
21-6	3719-3722	the	_
21-7	3723-3727	time	_
21-8	3728-3733	since	_
21-9	3734-3735	a	_
21-10	3736-3745	cigarette	_
21-11	3746-3749	was	_
21-12	3750-3754	last	_
21-13	3755-3761	smoked	_
21-14	3762-3770	relative	_
21-15	3771-3773	to	_
21-16	3774-3777	all	_
21-17	3778-3783	study	_
21-18	3784-3794	procedures	_
21-19	3795-3796	,	_
21-20	3797-3800	all	_
21-21	3801-3813	participants	_
21-22	3814-3816	in	_
21-23	3817-3821	both	_
21-24	3822-3829	cohorts	_
21-25	3830-3836	smoked	_
21-26	3837-3840	one	_
21-27	3841-3843	of	_
21-28	3844-3849	their	_
21-29	3850-3853	own	_
21-30	3854-3864	cigarettes	_
21-31	3865-3870	after	_
21-32	3871-3878	signing	_
21-33	3879-3882	the	_
21-34	3883-3891	informed	_
21-35	3892-3899	consent	_
21-36	3900-3913	approximately	_
21-37	3914-3917	1.5	_
21-38	3918-3923	hours	_
21-39	3924-3929	prior	_
21-40	3930-3932	to	_
21-41	3933-3935	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
21-42	3936-3944	scanning	_
21-43	3945-3946	.	_

Text=Expired carbon monoxide was measured immediately before and after scanning.
22-1	3947-3954	Expired	_
22-2	3955-3961	carbon	_
22-3	3962-3970	monoxide	_
22-4	3971-3974	was	_
22-5	3975-3983	measured	_
22-6	3984-3995	immediately	_
22-7	3996-4002	before	_
22-8	4003-4006	and	_
22-9	4007-4012	after	_
22-10	4013-4021	scanning	_
22-11	4022-4023	.	_

Text=Subjective craving to smoking and neutral images also was assessed after scanning by asking participants to rate how much craving they experienced when viewing each image on a five-point scale.
23-1	4024-4034	Subjective	_
23-2	4035-4042	craving	_
23-3	4043-4045	to	_
23-4	4046-4053	smoking	_
23-5	4054-4057	and	_
23-6	4058-4065	neutral	_
23-7	4066-4072	images	_
23-8	4073-4077	also	_
23-9	4078-4081	was	_
23-10	4082-4090	assessed	_
23-11	4091-4096	after	_
23-12	4097-4105	scanning	_
23-13	4106-4108	by	_
23-14	4109-4115	asking	_
23-15	4116-4128	participants	_
23-16	4129-4131	to	_
23-17	4132-4136	rate	_
23-18	4137-4140	how	_
23-19	4141-4145	much	_
23-20	4146-4153	craving	_
23-21	4154-4158	they	_
23-22	4159-4170	experienced	_
23-23	4171-4175	when	_
23-24	4176-4183	viewing	_
23-25	4184-4188	each	_
23-26	4189-4194	image	_
23-27	4195-4197	on	_
23-28	4198-4199	a	_
23-29	4200-4210	five-point	_
23-30	4211-4216	scale	_
23-31	4217-4218	.	_

Text=Acquisition parameters were identical between cohorts.
24-1	4219-4230	Acquisition	_
24-2	4231-4241	parameters	_
24-3	4242-4246	were	_
24-4	4247-4256	identical	_
24-5	4257-4264	between	_
24-6	4265-4272	cohorts	_
24-7	4273-4274	.	_

Text=Imaging was completed on a Siemens Trio 3T (2.89T) scanner (Erlangen, Germany) using a 32-channel head coil.
25-1	4275-4282	Imaging	_
25-2	4283-4286	was	_
25-3	4287-4296	completed	_
25-4	4297-4299	on	_
25-5	4300-4301	a	_
25-6	4302-4309	Siemens	_
25-7	4310-4314	Trio	_
25-8	4315-4317	3T	_
25-9	4318-4319	(	_
25-10	4320-4325	2.89T	_
25-11	4326-4327	)	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
25-12	4328-4335	scanner	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
25-13	4336-4337	(	_
25-14	4338-4346	Erlangen	_
25-15	4347-4348	,	_
25-16	4349-4356	Germany	_
25-17	4357-4358	)	_
25-18	4359-4364	using	_
25-19	4365-4366	a	_
25-20	4367-4377	32-channel	_
25-21	4378-4382	head	_
25-22	4383-4387	coil	_
25-23	4388-4389	.	_

Text=Multiecho multi-planar rapidly acquired gradient echostructural images were acquired with the following parameters (TR = 2.1 s, TE = 3.3 ms, slices = 128, matrix = 256 × 256, flip angle 7 degrees, resolution = 1.0 × 1.0 × 1.33 mm).
26-1	4390-4399	Multiecho	_
26-2	4400-4412	multi-planar	_
26-3	4413-4420	rapidly	_
26-4	4421-4429	acquired	_
26-5	4430-4438	gradient	_
26-6	4439-4453	echostructural	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-7	4454-4460	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-8	4461-4465	were	_
26-9	4466-4474	acquired	_
26-10	4475-4479	with	_
26-11	4480-4483	the	_
26-12	4484-4493	following	_
26-13	4494-4504	parameters	_
26-14	4505-4506	(	_
26-15	4507-4509	TR	_
26-16	4510-4511	=	_
26-17	4512-4515	2.1	_
26-18	4516-4517	s	_
26-19	4518-4519	,	_
26-20	4520-4522	TE	_
26-21	4523-4524	=	_
26-22	4525-4528	3.3	_
26-23	4529-4531	ms	_
26-24	4532-4533	,	_
26-25	4534-4540	slices	_
26-26	4541-4542	=	_
26-27	4543-4546	128	_
26-28	4547-4548	,	_
26-29	4549-4555	matrix	_
26-30	4556-4557	=	_
26-31	4558-4561	256	_
26-32	4562-4563	×	_
26-33	4564-4567	256	_
26-34	4568-4569	,	_
26-35	4570-4574	flip	_
26-36	4575-4580	angle	_
26-37	4581-4582	7	_
26-38	4583-4590	degrees	_
26-39	4591-4592	,	_
26-40	4593-4603	resolution	_
26-41	4604-4605	=	_
26-42	4606-4609	1.0	_
26-43	4610-4611	×	_
26-44	4612-4615	1.0	_
26-45	4616-4617	×	_
26-46	4618-4622	1.33	_
26-47	4623-4625	mm	_
26-48	4626-4627	)	_
26-49	4628-4629	.	_

Text=Task-related fMRI was collected using a gradient echo echoplanar sequence with the following parameters (TR = 2 s, TE = 30 ms, flip angle = 75 degrees, slices = 37, distance factor 10%, voxel size = 3.5 mm isotropic and a GRAPPA acceleration factor of 2).
27-1	4630-4642	Task-related	_
27-2	4643-4647	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
27-3	4648-4651	was	_
27-4	4652-4661	collected	_
27-5	4662-4667	using	_
27-6	4668-4669	a	_
27-7	4670-4678	gradient	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
27-8	4679-4683	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
27-9	4684-4694	echoplanar	_
27-10	4695-4703	sequence	_
27-11	4704-4708	with	_
27-12	4709-4712	the	_
27-13	4713-4722	following	_
27-14	4723-4733	parameters	_
27-15	4734-4735	(	_
27-16	4736-4738	TR	_
27-17	4739-4740	=	_
27-18	4741-4742	2	_
27-19	4743-4744	s	_
27-20	4745-4746	,	_
27-21	4747-4749	TE	_
27-22	4750-4751	=	_
27-23	4752-4754	30	_
27-24	4755-4757	ms	_
27-25	4758-4759	,	_
27-26	4760-4764	flip	_
27-27	4765-4770	angle	_
27-28	4771-4772	=	_
27-29	4773-4775	75	_
27-30	4776-4783	degrees	_
27-31	4784-4785	,	_
27-32	4786-4792	slices	_
27-33	4793-4794	=	_
27-34	4795-4797	37	_
27-35	4798-4799	,	_
27-36	4800-4808	distance	_
27-37	4809-4815	factor	_
27-38	4816-4818	10	_
27-39	4819-4820	%	_
27-40	4821-4822	,	_
27-41	4823-4828	voxel	_
27-42	4829-4833	size	_
27-43	4834-4835	=	_
27-44	4836-4839	3.5	_
27-45	4840-4842	mm	_
27-46	4843-4852	isotropic	_
27-47	4853-4856	and	_
27-48	4857-4858	a	_
27-49	4859-4865	GRAPPA	_
27-50	4866-4878	acceleration	_
27-51	4879-4885	factor	_
27-52	4886-4888	of	_
27-53	4889-4890	2	_
27-54	4891-4892	)	_
27-55	4893-4894	.	_

Text=2.3 Magnetic Resonance Spectroscopy Magnetic Resonance Spectroscopy also was identical between cohorts and was collected following procedures outlined in our prior work.
28-1	4895-4898	2.3	_
28-2	4899-4907	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
28-3	4908-4917	Resonance	_
28-4	4918-4930	Spectroscopy	_
28-5	4931-4939	Magnetic	_
28-6	4940-4949	Resonance	_
28-7	4950-4962	Spectroscopy	_
28-8	4963-4967	also	_
28-9	4968-4971	was	_
28-10	4972-4981	identical	_
28-11	4982-4989	between	_
28-12	4990-4997	cohorts	_
28-13	4998-5001	and	_
28-14	5002-5005	was	_
28-15	5006-5015	collected	_
28-16	5016-5025	following	_
28-17	5026-5036	procedures	_
28-18	5037-5045	outlined	_
28-19	5046-5048	in	_
28-20	5049-5052	our	_
28-21	5053-5058	prior	_
28-22	5059-5063	work	_
28-23	5064-5065	.	_

Text=Proton spectra were acquired using a modified J-resolved PRESS protocol (two-dimensional (2D) -JPRESS).
29-1	5066-5072	Proton	_
29-2	5073-5080	spectra	_
29-3	5081-5085	were	_
29-4	5086-5094	acquired	_
29-5	5095-5100	using	_
29-6	5101-5102	a	_
29-7	5103-5111	modified	_
29-8	5112-5122	J-resolved	_
29-9	5123-5128	PRESS	_
29-10	5129-5137	protocol	_
29-11	5138-5139	(	_
29-12	5140-5155	two-dimensional	_
29-13	5156-5157	(	_
29-14	5158-5160	2D	_
29-15	5161-5162	)	_
29-16	5163-5170	-JPRESS	_
29-17	5171-5172	)	_
29-18	5173-5174	.	_

Text=A single 2 × 2 × 3 cm voxel was placed in the dACC using the high-resolution T1-weighted anatomical images.
30-1	5175-5176	A	_
30-2	5177-5183	single	_
30-3	5184-5185	2	_
30-4	5186-5187	×	_
30-5	5188-5189	2	_
30-6	5190-5191	×	_
30-7	5192-5193	3	_
30-8	5194-5196	cm	_
30-9	5197-5202	voxel	_
30-10	5203-5206	was	_
30-11	5207-5213	placed	_
30-12	5214-5216	in	_
30-13	5217-5220	the	_
30-14	5221-5225	dACC	_
30-15	5226-5231	using	_
30-16	5232-5235	the	_
30-17	5236-5251	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
30-18	5252-5263	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-19	5264-5274	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-20	5275-5281	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-21	5282-5283	.	_

Text=Shimming of the magnetic field within the prescribed voxel was done automatically using an automated shimming routine.
31-1	5284-5292	Shimming	_
31-2	5293-5295	of	_
31-3	5296-5299	the	_
31-4	5300-5308	magnetic	_
31-5	5309-5314	field	_
31-6	5315-5321	within	_
31-7	5322-5325	the	_
31-8	5326-5336	prescribed	_
31-9	5337-5342	voxel	_
31-10	5343-5346	was	_
31-11	5347-5351	done	_
31-12	5352-5365	automatically	_
31-13	5366-5371	using	_
31-14	5372-5374	an	_
31-15	5375-5384	automated	_
31-16	5385-5393	shimming	_
31-17	5394-5401	routine	_
31-18	5402-5403	.	_

Text=Automated optimization also included water suppression power, carrier frequency, tip angles, and coil tuning.
32-1	5404-5413	Automated	_
32-2	5414-5426	optimization	_
32-3	5427-5431	also	_
32-4	5432-5440	included	_
32-5	5441-5446	water	_
32-6	5447-5458	suppression	_
32-7	5459-5464	power	_
32-8	5465-5466	,	_
32-9	5467-5474	carrier	_
32-10	5475-5484	frequency	_
32-11	5485-5486	,	_
32-12	5487-5490	tip	_
32-13	5491-5497	angles	_
32-14	5498-5499	,	_
32-15	5500-5503	and	_
32-16	5504-5508	coil	_
32-17	5509-5515	tuning	_
32-18	5516-5517	.	_

Text=The 2D-JPRESS sequence collected 22 echo time (TE) -stepped spectra with the TE ranging from 30 to 350 ms in 15 ms increments.
33-1	5518-5521	The	_
33-2	5522-5531	2D-JPRESS	http://maven.renci.org/NeuroBridge/neurobridge#Depression
33-3	5532-5540	sequence	_
33-4	5541-5550	collected	_
33-5	5551-5553	22	_
33-6	5554-5558	echo	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
33-7	5559-5563	time	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
33-8	5564-5565	(	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
33-9	5566-5568	TE	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
33-10	5569-5570	)	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
33-11	5571-5579	-stepped	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
33-12	5580-5587	spectra	_
33-13	5588-5592	with	_
33-14	5593-5596	the	_
33-15	5597-5599	TE	_
33-16	5600-5607	ranging	_
33-17	5608-5612	from	_
33-18	5613-5615	30	_
33-19	5616-5618	to	_
33-20	5619-5622	350	_
33-21	5623-5625	ms	_
33-22	5626-5628	in	_
33-23	5629-5631	15	_
33-24	5632-5634	ms	_
33-25	5635-5645	increments	_
33-26	5646-5647	.	_

Text=Acquisition parameters were: TR: 2 s, acquisition bandwidth = 67 Hz, spectral bandwith = 2 kHz, readout duration = 512 ms, NEX = 16/TE-step.
34-1	5648-5659	Acquisition	_
34-2	5660-5670	parameters	_
34-3	5671-5675	were	_
34-4	5676-5677	:	_
34-5	5678-5680	TR	_
34-6	5681-5682	:	_
34-7	5683-5684	2	_
34-8	5685-5686	s	_
34-9	5687-5688	,	_
34-10	5689-5700	acquisition	_
34-11	5701-5710	bandwidth	_
34-12	5711-5712	=	_
34-13	5713-5715	67	_
34-14	5716-5718	Hz	_
34-15	5719-5720	,	_
34-16	5721-5729	spectral	_
34-17	5730-5738	bandwith	_
34-18	5739-5740	=	_
34-19	5741-5742	2	_
34-20	5743-5746	kHz	_
34-21	5747-5748	,	_
34-22	5749-5756	readout	_
34-23	5757-5765	duration	_
34-24	5766-5767	=	_
34-25	5768-5771	512	_
34-26	5772-5774	ms	_
34-27	5775-5776	,	_
34-28	5777-5780	NEX	_
34-29	5781-5782	=	_
34-30	5783-5793	16/TE-step	_
34-31	5794-5795	.	_

Text=2.4 MRS Processing and Analysis To quantify Glu with the JPRESS data, the 22 TE-stepped free-induction decay was zero-filled out to 64 points, Gaussian-filtered and Fourier transformed.
35-1	5796-5799	2.4	_
35-2	5800-5803	MRS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
35-3	5804-5814	Processing	_
35-4	5815-5818	and	_
35-5	5819-5827	Analysis	_
35-6	5828-5830	To	_
35-7	5831-5839	quantify	_
35-8	5840-5843	Glu	_
35-9	5844-5848	with	_
35-10	5849-5852	the	_
35-11	5853-5859	JPRESS	_
35-12	5860-5864	data	_
35-13	5865-5866	,	_
35-14	5867-5870	the	_
35-15	5871-5873	22	_
35-16	5874-5884	TE-stepped	_
35-17	5885-5899	free-induction	_
35-18	5900-5905	decay	_
35-19	5906-5909	was	_
35-20	5910-5921	zero-filled	_
35-21	5922-5925	out	_
35-22	5926-5928	to	_
35-23	5929-5931	64	_
35-24	5932-5938	points	_
35-25	5939-5940	,	_
35-26	5941-5958	Gaussian-filtered	_
35-27	5959-5962	and	_
35-28	5963-5970	Fourier	_
35-29	5971-5982	transformed	_
35-30	5983-5984	.	_

Text=Using our previously published methods, every J-resolved spectral extraction (64 in total) within the 67 Hz bandwith was fitted with LCModel and its theoretically-correct template, which is optimized GAMMA-simulated J-resolved basis sets modeled for 2.89 T. All spectral data were modeled for 2.89 T field strength (123.05 MHz) to match that of our TRIO scanner.
36-1	5985-5990	Using	_
36-2	5991-5994	our	_
36-3	5995-6005	previously	_
36-4	6006-6015	published	_
36-5	6016-6023	methods	_
36-6	6024-6025	,	_
36-7	6026-6031	every	_
36-8	6032-6042	J-resolved	_
36-9	6043-6051	spectral	_
36-10	6052-6062	extraction	_
36-11	6063-6064	(	_
36-12	6065-6067	64	_
36-13	6068-6070	in	_
36-14	6071-6076	total	_
36-15	6077-6078	)	_
36-16	6079-6085	within	_
36-17	6086-6089	the	_
36-18	6090-6092	67	_
36-19	6093-6095	Hz	_
36-20	6096-6104	bandwith	_
36-21	6105-6108	was	_
36-22	6109-6115	fitted	_
36-23	6116-6120	with	_
36-24	6121-6128	LCModel	_
36-25	6129-6132	and	_
36-26	6133-6136	its	_
36-27	6137-6158	theoretically-correct	_
36-28	6159-6167	template	_
36-29	6168-6169	,	_
36-30	6170-6175	which	_
36-31	6176-6178	is	_
36-32	6179-6188	optimized	_
36-33	6189-6204	GAMMA-simulated	_
36-34	6205-6215	J-resolved	_
36-35	6216-6221	basis	_
36-36	6222-6226	sets	_
36-37	6227-6234	modeled	_
36-38	6235-6238	for	_
36-39	6239-6243	2.89	_
36-40	6244-6246	T.	_
36-41	6247-6250	All	_
36-42	6251-6259	spectral	_
36-43	6260-6264	data	_
36-44	6265-6269	were	_
36-45	6270-6277	modeled	_
36-46	6278-6281	for	_
36-47	6282-6286	2.89	_
36-48	6287-6288	T	_
36-49	6289-6294	field	_
36-50	6295-6303	strength	_
36-51	6304-6305	(	_
36-52	6306-6312	123.05	_
36-53	6313-6316	MHz	_
36-54	6317-6318	)	_
36-55	6319-6321	to	_
36-56	6322-6327	match	_
36-57	6328-6332	that	_
36-58	6333-6335	of	_
36-59	6336-6339	our	_
36-60	6340-6344	TRIO	_
36-61	6345-6352	scanner	_
36-62	6353-6354	.	_

Text=The integrated area under the 2D surface for each metabolite was calculated by summing the raw peak areas across all 64 J-resolved extractions.
37-1	6355-6358	The	_
37-2	6359-6369	integrated	_
37-3	6370-6374	area	_
37-4	6375-6380	under	_
37-5	6381-6384	the	_
37-6	6385-6387	2D	_
37-7	6388-6395	surface	_
37-8	6396-6399	for	_
37-9	6400-6404	each	_
37-10	6405-6415	metabolite	_
37-11	6416-6419	was	_
37-12	6420-6430	calculated	_
37-13	6431-6433	by	_
37-14	6434-6441	summing	_
37-15	6442-6445	the	_
37-16	6446-6449	raw	_
37-17	6450-6454	peak	_
37-18	6455-6460	areas	_
37-19	6461-6467	across	_
37-20	6468-6471	all	_
37-21	6472-6474	64	_
37-22	6475-6485	J-resolved	_
37-23	6486-6497	extractions	_
37-24	6498-6499	.	_

Text=Glutamate metabolites were expressed as ratios of total creatine (Cr).
38-1	6500-6509	Glutamate	_
38-2	6510-6521	metabolites	_
38-3	6522-6526	were	_
38-4	6527-6536	expressed	_
38-5	6537-6539	as	_
38-6	6540-6546	ratios	_
38-7	6547-6549	of	_
38-8	6550-6555	total	_
38-9	6556-6564	creatine	_
38-10	6565-6566	(	_
38-11	6567-6569	Cr	_
38-12	6570-6571	)	_
38-13	6572-6573	.	_

Text=2.5 Image Segmentation/voxel Tissue Analysis As in our prior work, all image segmentation was performed using FSL.
39-1	6574-6577	2.5	_
39-2	6578-6583	Image	_
39-3	6584-6602	Segmentation/voxel	_
39-4	6603-6609	Tissue	_
39-5	6610-6618	Analysis	_
39-6	6619-6621	As	_
39-7	6622-6624	in	_
39-8	6625-6628	our	_
39-9	6629-6634	prior	_
39-10	6635-6639	work	_
39-11	6640-6641	,	_
39-12	6642-6645	all	_
39-13	6646-6651	image	_
39-14	6652-6664	segmentation	_
39-15	6665-6668	was	_
39-16	6669-6678	performed	_
39-17	6679-6684	using	_
39-18	6685-6688	FSL	_
39-19	6689-6690	.	_

Text=The FSL segmentation tool was used to automatically segment cortical gray matter (GM), white matter (WM), and cerebral spinal fluid (CSF).
40-1	6691-6694	The	_
40-2	6695-6698	FSL	_
40-3	6699-6711	segmentation	_
40-4	6712-6716	tool	_
40-5	6717-6720	was	_
40-6	6721-6725	used	_
40-7	6726-6728	to	_
40-8	6729-6742	automatically	_
40-9	6743-6750	segment	_
40-10	6751-6759	cortical	_
40-11	6760-6764	gray	_
40-12	6765-6771	matter	_
40-13	6772-6773	(	_
40-14	6774-6776	GM	_
40-15	6777-6778	)	_
40-16	6779-6780	,	_
40-17	6781-6786	white	_
40-18	6787-6793	matter	_
40-19	6794-6795	(	_
40-20	6796-6798	WM	_
40-21	6799-6800	)	_
40-22	6801-6802	,	_
40-23	6803-6806	and	_
40-24	6807-6815	cerebral	_
40-25	6816-6822	spinal	_
40-26	6823-6828	fluid	_
40-27	6829-6830	(	_
40-28	6831-6834	CSF	_
40-29	6835-6836	)	_
40-30	6837-6838	.	_

Text=These segmented images were evaluated using an automated voxel coregistration and partial-volume analysis in-house program written in C-code.
41-1	6839-6844	These	_
41-2	6845-6854	segmented	_
41-3	6855-6861	images	_
41-4	6862-6866	were	_
41-5	6867-6876	evaluated	_
41-6	6877-6882	using	_
41-7	6883-6885	an	_
41-8	6886-6895	automated	_
41-9	6896-6901	voxel	_
41-10	6902-6916	coregistration	_
41-11	6917-6920	and	_
41-12	6921-6935	partial-volume	_
41-13	6936-6944	analysis	_
41-14	6945-6953	in-house	_
41-15	6954-6961	program	_
41-16	6962-6969	written	_
41-17	6970-6972	in	_
41-18	6973-6979	C-code	_
41-19	6980-6981	.	_

Text=Subsequently, the volumetric tissue contribution for each oblique dACC voxel was determined and volumetric contributions of total GM, WM, and CSF calculated.
42-1	6982-6994	Subsequently	_
42-2	6995-6996	,	_
42-3	6997-7000	the	_
42-4	7001-7011	volumetric	_
42-5	7012-7018	tissue	_
42-6	7019-7031	contribution	_
42-7	7032-7035	for	_
42-8	7036-7040	each	_
42-9	7041-7048	oblique	_
42-10	7049-7053	dACC	_
42-11	7054-7059	voxel	_
42-12	7060-7063	was	_
42-13	7064-7074	determined	_
42-14	7075-7078	and	_
42-15	7079-7089	volumetric	_
42-16	7090-7103	contributions	_
42-17	7104-7106	of	_
42-18	7107-7112	total	_
42-19	7113-7115	GM	_
42-20	7116-7117	,	_
42-21	7118-7120	WM	_
42-22	7121-7122	,	_
42-23	7123-7126	and	_
42-24	7127-7130	CSF	_
42-25	7131-7141	calculated	_
42-26	7142-7143	.	_

Text=2.6 fMRI and Smoking Cues Evaluating brain reactivity to smoking> neutral cues was done in the context of one of two studies involving either the traditional cue reactivity task or working memory for smoking cues.
43-1	7144-7147	2.6	_
43-2	7148-7152	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
43-3	7153-7156	and	_
43-4	7157-7164	Smoking	_
43-5	7165-7169	Cues	_
43-6	7170-7180	Evaluating	_
43-7	7181-7186	brain	_
43-8	7187-7197	reactivity	_
43-9	7198-7200	to	_
43-10	7201-7208	smoking	_
43-11	7209-7210	>	_
43-12	7211-7218	neutral	_
43-13	7219-7223	cues	_
43-14	7224-7227	was	_
43-15	7228-7232	done	_
43-16	7233-7235	in	_
43-17	7236-7239	the	_
43-18	7240-7247	context	_
43-19	7248-7250	of	_
43-20	7251-7254	one	_
43-21	7255-7257	of	_
43-22	7258-7261	two	_
43-23	7262-7269	studies	_
43-24	7270-7279	involving	_
43-25	7280-7286	either	_
43-26	7287-7290	the	_
43-27	7291-7302	traditional	_
43-28	7303-7306	cue	_
43-29	7307-7317	reactivity	_
43-30	7318-7322	task	_
43-31	7323-7325	or	_
43-32	7326-7333	working	_
43-33	7334-7340	memory	_
43-34	7341-7344	for	_
43-35	7345-7352	smoking	_
43-36	7353-7357	cues	_
43-37	7358-7359	.	_

Text=These tasks are explained in detail in our prior work.
44-1	7360-7365	These	_
44-2	7366-7371	tasks	_
44-3	7372-7375	are	_
44-4	7376-7385	explained	_
44-5	7386-7388	in	_
44-6	7389-7395	detail	_
44-7	7396-7398	in	_
44-8	7399-7402	our	_
44-9	7403-7408	prior	_
44-10	7409-7413	work	_
44-11	7414-7415	.	_

Text=In both tasks, the same smoking and neutral cues were used.
45-1	7416-7418	In	_
45-2	7419-7423	both	_
45-3	7424-7429	tasks	_
45-4	7430-7431	,	_
45-5	7432-7435	the	_
45-6	7436-7440	same	_
45-7	7441-7448	smoking	_
45-8	7449-7452	and	_
45-9	7453-7460	neutral	_
45-10	7461-7465	cues	_
45-11	7466-7470	were	_
45-12	7471-7475	used	_
45-13	7476-7477	.	_

Text=Smoking images included smoking-related content such as people smoking, people holding cigarettes, or cigarettes alone.
46-1	7478-7485	Smoking	_
46-2	7486-7492	images	_
46-3	7493-7501	included	_
46-4	7502-7517	smoking-related	_
46-5	7518-7525	content	_
46-6	7526-7530	such	_
46-7	7531-7533	as	_
46-8	7534-7540	people	_
46-9	7541-7548	smoking	_
46-10	7549-7550	,	_
46-11	7551-7557	people	_
46-12	7558-7565	holding	_
46-13	7566-7576	cigarettes	_
46-14	7577-7578	,	_
46-15	7579-7581	or	_
46-16	7582-7592	cigarettes	_
46-17	7593-7598	alone	_
46-18	7599-7600	.	_

Text=Neutral images were matched for content in that they involved people, hands, or objects such as pens or paintbrushes.
47-1	7601-7608	Neutral	_
47-2	7609-7615	images	_
47-3	7616-7620	were	_
47-4	7621-7628	matched	_
47-5	7629-7632	for	_
47-6	7633-7640	content	_
47-7	7641-7643	in	_
47-8	7644-7648	that	_
47-9	7649-7653	they	_
47-10	7654-7662	involved	_
47-11	7663-7669	people	_
47-12	7670-7671	,	_
47-13	7672-7677	hands	_
47-14	7678-7679	,	_
47-15	7680-7682	or	_
47-16	7683-7690	objects	_
47-17	7691-7695	such	_
47-18	7696-7698	as	_
47-19	7699-7703	pens	_
47-20	7704-7706	or	_
47-21	7707-7719	paintbrushes	_
47-22	7720-7721	.	_

Text=In the traditional cue-reactivity task, presented to our primary cohort, target images were also presented to ensure participants were awake and attending to the task.
48-1	7722-7724	In	_
48-2	7725-7728	the	_
48-3	7729-7740	traditional	_
48-4	7741-7755	cue-reactivity	_
48-5	7756-7760	task	_
48-6	7761-7762	,	_
48-7	7763-7772	presented	_
48-8	7773-7775	to	_
48-9	7776-7779	our	_
48-10	7780-7787	primary	_
48-11	7788-7794	cohort	_
48-12	7795-7796	,	_
48-13	7797-7803	target	_
48-14	7804-7810	images	_
48-15	7811-7815	were	_
48-16	7816-7820	also	_
48-17	7821-7830	presented	_
48-18	7831-7833	to	_
48-19	7834-7840	ensure	_
48-20	7841-7853	participants	_
48-21	7854-7858	were	_
48-22	7859-7864	awake	_
48-23	7865-7868	and	_
48-24	7869-7878	attending	_
48-25	7879-7881	to	_
48-26	7882-7885	the	_
48-27	7886-7890	task	_
48-28	7891-7892	.	_

Text=Targets were pictures of animals and participants were asked to press a button when a target appeared.
49-1	7893-7900	Targets	_
49-2	7901-7905	were	_
49-3	7906-7914	pictures	_
49-4	7915-7917	of	_
49-5	7918-7925	animals	_
49-6	7926-7929	and	_
49-7	7930-7942	participants	_
49-8	7943-7947	were	_
49-9	7948-7953	asked	_
49-10	7954-7956	to	_
49-11	7957-7962	press	_
49-12	7963-7964	a	_
49-13	7965-7971	button	_
49-14	7972-7976	when	_
49-15	7977-7978	a	_
49-16	7979-7985	target	_
49-17	7986-7994	appeared	_
49-18	7995-7996	.	_

Text=This data only was used to ensure participants were attending to the task.
50-1	7997-8001	This	_
50-2	8002-8006	data	_
50-3	8007-8011	only	_
50-4	8012-8015	was	_
50-5	8016-8020	used	_
50-6	8021-8023	to	_
50-7	8024-8030	ensure	_
50-8	8031-8043	participants	_
50-9	8044-8048	were	_
50-10	8049-8058	attending	_
50-11	8059-8061	to	_
50-12	8062-8065	the	_
50-13	8066-8070	task	_
50-14	8071-8072	.	_

Text=Our primary cohort was shown 60 smoking, 60 neutral and 12 target images divided evenly across 5 blocks lasting 5 m and 18 s each.
51-1	8073-8076	Our	_
51-2	8077-8084	primary	_
51-3	8085-8091	cohort	_
51-4	8092-8095	was	_
51-5	8096-8101	shown	_
51-6	8102-8104	60	_
51-7	8105-8112	smoking	_
51-8	8113-8114	,	_
51-9	8115-8117	60	_
51-10	8118-8125	neutral	_
51-11	8126-8129	and	_
51-12	8130-8132	12	_
51-13	8133-8139	target	_
51-14	8140-8146	images	_
51-15	8147-8154	divided	_
51-16	8155-8161	evenly	_
51-17	8162-8168	across	_
51-18	8169-8170	5	_
51-19	8171-8177	blocks	_
51-20	8178-8185	lasting	_
51-21	8186-8187	5	_
51-22	8188-8189	m	_
51-23	8190-8193	and	_
51-24	8194-8196	18	_
51-25	8197-8198	s	_
51-26	8199-8203	each	_
51-27	8204-8205	.	_

Text=Images were presented for 4 s in a pseudorandom order with no more than 2 of the same picture type occurring in a row as performed in our prior work.
52-1	8206-8212	Images	_
52-2	8213-8217	were	_
52-3	8218-8227	presented	_
52-4	8228-8231	for	_
52-5	8232-8233	4	_
52-6	8234-8235	s	_
52-7	8236-8238	in	_
52-8	8239-8240	a	_
52-9	8241-8253	pseudorandom	_
52-10	8254-8259	order	_
52-11	8260-8264	with	_
52-12	8265-8267	no	_
52-13	8268-8272	more	_
52-14	8273-8277	than	_
52-15	8278-8279	2	_
52-16	8280-8282	of	_
52-17	8283-8286	the	_
52-18	8287-8291	same	_
52-19	8292-8299	picture	_
52-20	8300-8304	type	_
52-21	8305-8314	occurring	_
52-22	8315-8317	in	_
52-23	8318-8319	a	_
52-24	8320-8323	row	_
52-25	8324-8326	as	_
52-26	8327-8336	performed	_
52-27	8337-8339	in	_
52-28	8340-8343	our	_
52-29	8344-8349	prior	_
52-30	8350-8354	work	_
52-31	8355-8356	.	_

Text=Images were divided by a jittered inter-trial-interval ranging from 6 – 14s in intervals of 2 s with a 10 s average across block.
53-1	8357-8363	Images	_
53-2	8364-8368	were	_
53-3	8369-8376	divided	_
53-4	8377-8379	by	_
53-5	8380-8381	a	_
53-6	8382-8390	jittered	_
53-7	8391-8411	inter-trial-interval	_
53-8	8412-8419	ranging	_
53-9	8420-8424	from	_
53-10	8425-8426	6	_
53-11	8427-8428	–	_
53-12	8429-8432	14s	_
53-13	8433-8435	in	_
53-14	8436-8445	intervals	_
53-15	8446-8448	of	_
53-16	8449-8450	2	_
53-17	8451-8452	s	_
53-18	8453-8457	with	_
53-19	8458-8459	a	_
53-20	8460-8462	10	_
53-21	8463-8464	s	_
53-22	8465-8472	average	_
53-23	8473-8479	across	_
53-24	8480-8485	block	_
53-25	8486-8487	.	_

Text=During this inter-trial interval, participants in the primary cohort were shown a white fixation cross on a black screen.
54-1	8488-8494	During	_
54-2	8495-8499	this	_
54-3	8500-8511	inter-trial	_
54-4	8512-8520	interval	_
54-5	8521-8522	,	_
54-6	8523-8535	participants	_
54-7	8536-8538	in	_
54-8	8539-8542	the	_
54-9	8543-8550	primary	_
54-10	8551-8557	cohort	_
54-11	8558-8562	were	_
54-12	8563-8568	shown	_
54-13	8569-8570	a	_
54-14	8571-8576	white	_
54-15	8577-8585	fixation	_
54-16	8586-8591	cross	_
54-17	8592-8594	on	_
54-18	8595-8596	a	_
54-19	8597-8602	black	_
54-20	8603-8609	screen	_
54-21	8610-8611	.	_

Text=The replication cohort was exposed to smoking cues in the context of the delay-match-to-sample working memory task.
55-1	8612-8615	The	_
55-2	8616-8627	replication	_
55-3	8628-8634	cohort	_
55-4	8635-8638	was	_
55-5	8639-8646	exposed	_
55-6	8647-8649	to	_
55-7	8650-8657	smoking	_
55-8	8658-8662	cues	_
55-9	8663-8665	in	_
55-10	8666-8669	the	_
55-11	8670-8677	context	_
55-12	8678-8680	of	_
55-13	8681-8684	the	_
55-14	8685-8706	delay-match-to-sample	_
55-15	8707-8714	working	_
55-16	8715-8721	memory	_
55-17	8722-8726	task	_
55-18	8727-8728	.	_

Text=For the purposes of the present study only the “ sample ” portion of this task was analyzed, as this corresponds most closely to the traditional cue-reactivity task.
56-1	8729-8732	For	_
56-2	8733-8736	the	_
56-3	8737-8745	purposes	_
56-4	8746-8748	of	_
56-5	8749-8752	the	_
56-6	8753-8760	present	_
56-7	8761-8766	study	_
56-8	8767-8771	only	_
56-9	8772-8775	the	_
56-10	8776-8777	“	_
56-11	8778-8784	sample	_
56-12	8785-8786	”	_
56-13	8787-8794	portion	_
56-14	8795-8797	of	_
56-15	8798-8802	this	_
56-16	8803-8807	task	_
56-17	8808-8811	was	_
56-18	8812-8820	analyzed	_
56-19	8821-8822	,	_
56-20	8823-8825	as	_
56-21	8826-8830	this	_
56-22	8831-8842	corresponds	_
56-23	8843-8847	most	_
56-24	8848-8855	closely	_
56-25	8856-8858	to	_
56-26	8859-8862	the	_
56-27	8863-8874	traditional	_
56-28	8875-8889	cue-reactivity	_
56-29	8890-8894	task	_
56-30	8895-8896	.	_

Text=During the sample period, participants were shown either a smoking or neutral image for 2 s that they would have to match to a subsequent image following a 10 s delay.
57-1	8897-8903	During	_
57-2	8904-8907	the	_
57-3	8908-8914	sample	_
57-4	8915-8921	period	_
57-5	8922-8923	,	_
57-6	8924-8936	participants	_
57-7	8937-8941	were	_
57-8	8942-8947	shown	_
57-9	8948-8954	either	_
57-10	8955-8956	a	_
57-11	8957-8964	smoking	_
57-12	8965-8967	or	_
57-13	8968-8975	neutral	_
57-14	8976-8981	image	_
57-15	8982-8985	for	_
57-16	8986-8987	2	_
57-17	8988-8989	s	_
57-18	8990-8994	that	_
57-19	8995-8999	they	_
57-20	9000-9005	would	_
57-21	9006-9010	have	_
57-22	9011-9013	to	_
57-23	9014-9019	match	_
57-24	9020-9022	to	_
57-25	9023-9024	a	_
57-26	9025-9035	subsequent	_
57-27	9036-9041	image	_
57-28	9042-9051	following	_
57-29	9052-9053	a	_
57-30	9054-9056	10	_
57-31	9057-9058	s	_
57-32	9059-9064	delay	_
57-33	9065-9066	.	_

Text=Thus, the sample period allows for the smoking> neutral contrast to be conducted without involving the working memory component involved in the other task elements and closely resembles the traditional cue reactivity task.
58-1	9067-9071	Thus	_
58-2	9072-9073	,	_
58-3	9074-9077	the	_
58-4	9078-9084	sample	_
58-5	9085-9091	period	_
58-6	9092-9098	allows	_
58-7	9099-9102	for	_
58-8	9103-9106	the	_
58-9	9107-9114	smoking	_
58-10	9115-9116	>	_
58-11	9117-9124	neutral	_
58-12	9125-9133	contrast	_
58-13	9134-9136	to	_
58-14	9137-9139	be	_
58-15	9140-9149	conducted	_
58-16	9150-9157	without	_
58-17	9158-9167	involving	_
58-18	9168-9171	the	_
58-19	9172-9179	working	_
58-20	9180-9186	memory	_
58-21	9187-9196	component	_
58-22	9197-9205	involved	_
58-23	9206-9208	in	_
58-24	9209-9212	the	_
58-25	9213-9218	other	_
58-26	9219-9223	task	_
58-27	9224-9232	elements	_
58-28	9233-9236	and	_
58-29	9237-9244	closely	_
58-30	9245-9254	resembles	_
58-31	9255-9258	the	_
58-32	9259-9270	traditional	_
58-33	9271-9274	cue	_
58-34	9275-9285	reactivity	_
58-35	9286-9290	task	_
58-36	9291-9292	.	_

Text=To insure participants were attending, only trials where participants performed accurately were included in the analysis.
59-1	9293-9295	To	_
59-2	9296-9302	insure	_
59-3	9303-9315	participants	_
59-4	9316-9320	were	_
59-5	9321-9330	attending	_
59-6	9331-9332	,	_
59-7	9333-9337	only	_
59-8	9338-9344	trials	_
59-9	9345-9350	where	_
59-10	9351-9363	participants	_
59-11	9364-9373	performed	_
59-12	9374-9384	accurately	_
59-13	9385-9389	were	_
59-14	9390-9398	included	_
59-15	9399-9401	in	_
59-16	9402-9405	the	_
59-17	9406-9414	analysis	_
59-18	9415-9416	.	_

Text=The majority of trials were included, as accuracy ranged from 0.92 ± 0.01 – 0.97 ± 0.07 depending on trial type.
60-1	9417-9420	The	_
60-2	9421-9429	majority	_
60-3	9430-9432	of	_
60-4	9433-9439	trials	_
60-5	9440-9444	were	_
60-6	9445-9453	included	_
60-7	9454-9455	,	_
60-8	9456-9458	as	_
60-9	9459-9467	accuracy	_
60-10	9468-9474	ranged	_
60-11	9475-9479	from	_
60-12	9480-9484	0.92	_
60-13	9485-9486	±	_
60-14	9487-9491	0.01	_
60-15	9492-9493	–	_
60-16	9494-9498	0.97	_
60-17	9499-9500	±	_
60-18	9501-9505	0.07	_
60-19	9506-9515	depending	_
60-20	9516-9518	on	_
60-21	9519-9524	trial	_
60-22	9525-9529	type	_
60-23	9530-9531	.	_

Text=2.7 fMRI Pre-Processing Tools from the fMRI of the brain (FMRIB) software Library (FSL; http: //www.fmrib.ox.ac.uk/fsl) were used to process all fMRI data.
61-1	9532-9535	2.7	_
61-2	9536-9540	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
61-3	9541-9555	Pre-Processing	_
61-4	9556-9561	Tools	_
61-5	9562-9566	from	_
61-6	9567-9570	the	_
61-7	9571-9575	fMRI	_
61-8	9576-9578	of	_
61-9	9579-9582	the	_
61-10	9583-9588	brain	_
61-11	9589-9590	(	_
61-12	9591-9596	FMRIB	_
61-13	9597-9598	)	_
61-14	9599-9607	software	_
61-15	9608-9615	Library	_
61-16	9616-9617	(	_
61-17	9618-9621	FSL	_
61-18	9622-9623	;	_
61-19	9624-9628	http	_
61-20	9629-9630	:	_
61-21	9631-9655	//www.fmrib.ox.ac.uk/fsl	_
61-22	9656-9657	)	_
61-23	9658-9662	were	_
61-24	9663-9667	used	_
61-25	9668-9670	to	_
61-26	9671-9678	process	_
61-27	9679-9682	all	_
61-28	9683-9687	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
61-29	9688-9692	data	_
61-30	9693-9694	.	_

Text=For all analyses, the first 5 volumes were removed to allow for signal stabilization.
62-1	9695-9698	For	_
62-2	9699-9702	all	_
62-3	9703-9711	analyses	_
62-4	9712-9713	,	_
62-5	9714-9717	the	_
62-6	9718-9723	first	_
62-7	9724-9725	5	_
62-8	9726-9733	volumes	_
62-9	9734-9738	were	_
62-10	9739-9746	removed	_
62-11	9747-9749	to	_
62-12	9750-9755	allow	_
62-13	9756-9759	for	_
62-14	9760-9766	signal	_
62-15	9767-9780	stabilization	_
62-16	9781-9782	.	_

Text=Functional data were then pre-processed including motion correction, brain extraction, slice timing correction, spatial smoothing with a Gaussian kernel for a full-width half-maximum 6 mm, and a high-pass temporal filter with Gaussian-weighted least-squares straight-line fitting with 100 s. Each individual participant ’ s data was registered to the MNI152 2 mm3 standard space template (Montreal Neurological Institute, Montreal, QC, Canada).
63-1	9783-9793	Functional	_
63-2	9794-9798	data	_
63-3	9799-9803	were	_
63-4	9804-9808	then	_
63-5	9809-9822	pre-processed	_
63-6	9823-9832	including	_
63-7	9833-9839	motion	_
63-8	9840-9850	correction	_
63-9	9851-9852	,	_
63-10	9853-9858	brain	_
63-11	9859-9869	extraction	_
63-12	9870-9871	,	_
63-13	9872-9877	slice	_
63-14	9878-9884	timing	_
63-15	9885-9895	correction	_
63-16	9896-9897	,	_
63-17	9898-9905	spatial	_
63-18	9906-9915	smoothing	_
63-19	9916-9920	with	_
63-20	9921-9922	a	_
63-21	9923-9931	Gaussian	_
63-22	9932-9938	kernel	_
63-23	9939-9942	for	_
63-24	9943-9944	a	_
63-25	9945-9955	full-width	_
63-26	9956-9968	half-maximum	_
63-27	9969-9970	6	_
63-28	9971-9973	mm	_
63-29	9974-9975	,	_
63-30	9976-9979	and	_
63-31	9980-9981	a	_
63-32	9982-9991	high-pass	_
63-33	9992-10000	temporal	_
63-34	10001-10007	filter	_
63-35	10008-10012	with	_
63-36	10013-10030	Gaussian-weighted	_
63-37	10031-10044	least-squares	_
63-38	10045-10058	straight-line	_
63-39	10059-10066	fitting	_
63-40	10067-10071	with	_
63-41	10072-10075	100	_
63-42	10076-10078	s.	_
63-43	10079-10083	Each	_
63-44	10084-10094	individual	_
63-45	10095-10106	participant	_
63-46	10107-10108	’	_
63-47	10109-10110	s	_
63-48	10111-10115	data	_
63-49	10116-10119	was	_
63-50	10120-10130	registered	_
63-51	10131-10133	to	_
63-52	10134-10137	the	_
63-53	10138-10144	MNI152	_
63-54	10145-10146	2	_
63-55	10147-10150	mm3	_
63-56	10151-10159	standard	_
63-57	10160-10165	space	_
63-58	10166-10174	template	_
63-59	10175-10176	(	_
63-60	10177-10185	Montreal	_
63-61	10186-10198	Neurological	_
63-62	10199-10208	Institute	_
63-63	10209-10210	,	_
63-64	10211-10219	Montreal	_
63-65	10220-10221	,	_
63-66	10222-10224	QC	_
63-67	10225-10226	,	_
63-68	10227-10233	Canada	_
63-69	10234-10235	)	_
63-70	10236-10237	.	_

Text=For task-related data, an in-house program used in our prior work was used to detect and adjust for artifacts generated by intensity spiking.
64-1	10238-10241	For	_
64-2	10242-10254	task-related	_
64-3	10255-10259	data	_
64-4	10260-10261	,	_
64-5	10262-10264	an	_
64-6	10265-10273	in-house	_
64-7	10274-10281	program	_
64-8	10282-10286	used	_
64-9	10287-10289	in	_
64-10	10290-10293	our	_
64-11	10294-10299	prior	_
64-12	10300-10304	work	_
64-13	10305-10308	was	_
64-14	10309-10313	used	_
64-15	10314-10316	to	_
64-16	10317-10323	detect	_
64-17	10324-10327	and	_
64-18	10328-10334	adjust	_
64-19	10335-10338	for	_
64-20	10339-10348	artifacts	_
64-21	10349-10358	generated	_
64-22	10359-10361	by	_
64-23	10362-10371	intensity	_
64-24	10372-10379	spiking	_
64-25	10380-10381	.	_

Text=2.8 Cue-Reactivity For both the traditional cue-reactivity and working memory tasks, the first-level analysis was conducted on each of the participant ’ s individual task runs separately and all task-related regressors were convolved with the gamma hemodynamic response function.
65-1	10382-10385	2.8	_
65-2	10386-10400	Cue-Reactivity	_
65-3	10401-10404	For	_
65-4	10405-10409	both	_
65-5	10410-10413	the	_
65-6	10414-10425	traditional	_
65-7	10426-10440	cue-reactivity	_
65-8	10441-10444	and	_
65-9	10445-10452	working	_
65-10	10453-10459	memory	_
65-11	10460-10465	tasks	_
65-12	10466-10467	,	_
65-13	10468-10471	the	_
65-14	10472-10483	first-level	_
65-15	10484-10492	analysis	_
65-16	10493-10496	was	_
65-17	10497-10506	conducted	_
65-18	10507-10509	on	_
65-19	10510-10514	each	_
65-20	10515-10517	of	_
65-21	10518-10521	the	_
65-22	10522-10533	participant	_
65-23	10534-10535	’	_
65-24	10536-10537	s	_
65-25	10538-10548	individual	_
65-26	10549-10553	task	_
65-27	10554-10558	runs	_
65-28	10559-10569	separately	_
65-29	10570-10573	and	_
65-30	10574-10577	all	_
65-31	10578-10590	task-related	_
65-32	10591-10601	regressors	_
65-33	10602-10606	were	_
65-34	10607-10616	convolved	_
65-35	10617-10621	with	_
65-36	10622-10625	the	_
65-37	10626-10631	gamma	_
65-38	10632-10643	hemodynamic	_
65-39	10644-10652	response	_
65-40	10653-10661	function	_
65-41	10662-10663	.	_

Text=Confound regressors representing motion were also included in the model.
66-1	10664-10672	Confound	_
66-2	10673-10683	regressors	_
66-3	10684-10696	representing	_
66-4	10697-10703	motion	_
66-5	10704-10708	were	_
66-6	10709-10713	also	_
66-7	10714-10722	included	_
66-8	10723-10725	in	_
66-9	10726-10729	the	_
66-10	10730-10735	model	_
66-11	10736-10737	.	_

Text=Contrasts were conducted between the smoking and neutral image conditions.
67-1	10738-10747	Contrasts	_
67-2	10748-10752	were	_
67-3	10753-10762	conducted	_
67-4	10763-10770	between	_
67-5	10771-10774	the	_
67-6	10775-10782	smoking	_
67-7	10783-10786	and	_
67-8	10787-10794	neutral	_
67-9	10795-10800	image	_
67-10	10801-10811	conditions	_
67-11	10812-10813	.	_

Text=For the working memory task these contrasts were conducted during the sample period of the delay-match-to-sample task.
68-1	10814-10817	For	_
68-2	10818-10821	the	_
68-3	10822-10829	working	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
68-4	10830-10836	memory	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
68-5	10837-10841	task	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
68-6	10842-10847	these	_
68-7	10848-10857	contrasts	_
68-8	10858-10862	were	_
68-9	10863-10872	conducted	_
68-10	10873-10879	during	_
68-11	10880-10883	the	_
68-12	10884-10890	sample	_
68-13	10891-10897	period	_
68-14	10898-10900	of	_
68-15	10901-10904	the	_
68-16	10905-10926	delay-match-to-sample	_
68-17	10927-10931	task	_
68-18	10932-10933	.	_

Text=In both instances, these lower level individual runs were combined in the second level to generate the average brain reactivity for each individual participant.
69-1	10934-10936	In	_
69-2	10937-10941	both	_
69-3	10942-10951	instances	_
69-4	10952-10953	,	_
69-5	10954-10959	these	_
69-6	10960-10965	lower	_
69-7	10966-10971	level	_
69-8	10972-10982	individual	_
69-9	10983-10987	runs	_
69-10	10988-10992	were	_
69-11	10993-11001	combined	_
69-12	11002-11004	in	_
69-13	11005-11008	the	_
69-14	11009-11015	second	_
69-15	11016-11021	level	_
69-16	11022-11024	to	_
69-17	11025-11033	generate	_
69-18	11034-11037	the	_
69-19	11038-11045	average	_
69-20	11046-11051	brain	_
69-21	11052-11062	reactivity	_
69-22	11063-11066	for	_
69-23	11067-11071	each	_
69-24	11072-11082	individual	_
69-25	11083-11094	participant	_
69-26	11095-11096	.	_

Text=For the primary cohort we conducted a group level mixed effects (FLAME) whole brain analysis for the smoking vs. neutral contrast.
70-1	11097-11100	For	_
70-2	11101-11104	the	_
70-3	11105-11112	primary	_
70-4	11113-11119	cohort	_
70-5	11120-11122	we	_
70-6	11123-11132	conducted	_
70-7	11133-11134	a	_
70-8	11135-11140	group	_
70-9	11141-11146	level	_
70-10	11147-11152	mixed	_
70-11	11153-11160	effects	_
70-12	11161-11162	(	_
70-13	11163-11168	FLAME	_
70-14	11169-11170	)	_
70-15	11171-11176	whole	_
70-16	11177-11182	brain	_
70-17	11183-11191	analysis	_
70-18	11192-11195	for	_
70-19	11196-11199	the	_
70-20	11200-11207	smoking	_
70-21	11208-11211	vs.	_
70-22	11212-11219	neutral	_
70-23	11220-11228	contrast	_
70-24	11229-11230	.	_

Text=Multiple comparisons were corrected to p <0.05 using a cluster-based threshold across the entire brain Z – 2.3.
71-1	11231-11239	Multiple	_
71-2	11240-11251	comparisons	_
71-3	11252-11256	were	_
71-4	11257-11266	corrected	_
71-5	11267-11269	to	_
71-6	11270-11271	p	_
71-7	11272-11273	<	_
71-8	11274-11278	0.05	_
71-9	11279-11284	using	_
71-10	11285-11286	a	_
71-11	11287-11300	cluster-based	_
71-12	11301-11310	threshold	_
71-13	11311-11317	across	_
71-14	11318-11321	the	_
71-15	11322-11328	entire	_
71-16	11329-11334	brain	_
71-17	11335-11336	Z	_
71-18	11337-11338	–	_
71-19	11339-11342	2.3	_
71-20	11343-11344	.	_

Text=This whole brain activation to the smoking vs. neutral contrast was compared to the DMN region of interest (ROI) defined by, Fig.1) by calculating the cross correlation between these maps using the FSL command fslcc.
72-1	11345-11349	This	_
72-2	11350-11355	whole	_
72-3	11356-11361	brain	_
72-4	11362-11372	activation	_
72-5	11373-11375	to	_
72-6	11376-11379	the	_
72-7	11380-11387	smoking	_
72-8	11388-11391	vs.	_
72-9	11392-11399	neutral	_
72-10	11400-11408	contrast	_
72-11	11409-11412	was	_
72-12	11413-11421	compared	_
72-13	11422-11424	to	_
72-14	11425-11428	the	_
72-15	11429-11432	DMN	_
72-16	11433-11439	region	_
72-17	11440-11442	of	_
72-18	11443-11451	interest	_
72-19	11452-11453	(	_
72-20	11454-11457	ROI	_
72-21	11458-11459	)	_
72-22	11460-11467	defined	_
72-23	11468-11470	by	_
72-24	11471-11472	,	_
72-25	11473-11478	Fig.1	_
72-26	11479-11480	)	_
72-27	11481-11483	by	_
72-28	11484-11495	calculating	_
72-29	11496-11499	the	_
72-30	11500-11505	cross	_
72-31	11506-11517	correlation	_
72-32	11518-11525	between	_
72-33	11526-11531	these	_
72-34	11532-11536	maps	_
72-35	11537-11542	using	_
72-36	11543-11546	the	_
72-37	11547-11550	FSL	_
72-38	11551-11558	command	_
72-39	11559-11564	fslcc	_
72-40	11565-11566	.	_

Text=To more directly evaluate how the DMN responds to smoking> neutral cues, beta-weights from the DMN ROI were extracted using FSL ’ s featquery from each individual.
73-1	11567-11569	To	_
73-2	11570-11574	more	_
73-3	11575-11583	directly	_
73-4	11584-11592	evaluate	_
73-5	11593-11596	how	_
73-6	11597-11600	the	_
73-7	11601-11604	DMN	_
73-8	11605-11613	responds	_
73-9	11614-11616	to	_
73-10	11617-11624	smoking	_
73-11	11625-11626	>	_
73-12	11627-11634	neutral	_
73-13	11635-11639	cues	_
73-14	11640-11641	,	_
73-15	11642-11654	beta-weights	_
73-16	11655-11659	from	_
73-17	11660-11663	the	_
73-18	11664-11667	DMN	_
73-19	11668-11671	ROI	_
73-20	11672-11676	were	_
73-21	11677-11686	extracted	_
73-22	11687-11692	using	_
73-23	11693-11696	FSL	_
73-24	11697-11698	’	_
73-25	11699-11700	s	_
73-26	11701-11710	featquery	_
73-27	11711-11715	from	_
73-28	11716-11720	each	_
73-29	11721-11731	individual	_
73-30	11732-11733	.	_

Text=The Pearson ’ s correlation coefficient was then calculated between DMN beta-weights and dACC Glu/Cr for each cohort to assess the association between these measures.
74-1	11734-11737	The	_
74-2	11738-11745	Pearson	_
74-3	11746-11747	’	_
74-4	11748-11749	s	_
74-5	11750-11761	correlation	_
74-6	11762-11773	coefficient	_
74-7	11774-11777	was	_
74-8	11778-11782	then	_
74-9	11783-11793	calculated	_
74-10	11794-11801	between	_
74-11	11802-11805	DMN	_
74-12	11806-11818	beta-weights	_
74-13	11819-11822	and	_
74-14	11823-11827	dACC	_
74-15	11828-11834	Glu/Cr	_
74-16	11835-11838	for	_
74-17	11839-11843	each	_
74-18	11844-11850	cohort	_
74-19	11851-11853	to	_
74-20	11854-11860	assess	_
74-21	11861-11864	the	_
74-22	11865-11876	association	_
74-23	11877-11884	between	_
74-24	11885-11890	these	_
74-25	11891-11899	measures	_
74-26	11900-11901	.	_

